These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. New Insights into Mechanisms of Immune Checkpoint Inhibitor-Induced Cardiovascular Toxicity. Khunger A; Battel L; Wadhawan A; More A; Kapoor A; Agrawal N Curr Oncol Rep; 2020 Jun; 22(7):65. PubMed ID: 32514647 [TBL] [Abstract][Full Text] [Related]
4. Challenges and solutions in management of cardiotoxicity induced by checkpoint inhibitors. Mladosievičová B; Országhová Z; Jablonická M; Rečková M; Chovanec M; Mego M Klin Onkol; 2020; 33(5):350-355. PubMed ID: 33108879 [TBL] [Abstract][Full Text] [Related]
15. Mechanisms and clinical manifestations of cardiovascular toxicities associated with immune checkpoint inhibitors. Baik AH; Tsai KK; Oh DY; Aras MA Clin Sci (Lond); 2021 Mar; 135(5):703-724. PubMed ID: 33686402 [TBL] [Abstract][Full Text] [Related]
16. Cardiovascular Toxicity Associated With Immune Checkpoint Inhibitor Therapy: A Comprehensive Review. Chitsazan M; Amin A; Ladel L; Baig A; Chitsazan M Crit Pathw Cardiol; 2023 Sep; 22(3):69-82. PubMed ID: 37363862 [TBL] [Abstract][Full Text] [Related]
17. What the Cardiologist Needs to Know About Cancer Immunotherapies and Complications. Frayberg M; Yung A; Zubiri L; Zlotoff DA; Reynolds KL Curr Treat Options Oncol; 2021 May; 22(6):53. PubMed ID: 34037918 [TBL] [Abstract][Full Text] [Related]
18. Heart-Specific Immune Responses in an Animal Model of Autoimmune-Related Myocarditis Mitigated by an Immunoproteasome Inhibitor and Genetic Ablation. Bockstahler M; Fischer A; Goetzke CC; Neumaier HL; Sauter M; Kespohl M; Müller AM; Meckes C; Salbach C; Schenk M; Heuser A; Landmesser U; Weiner J; Meder B; Lehmann L; Kratzer A; Klingel K; Katus HA; Kaya Z; Beling A Circulation; 2020 Jun; 141(23):1885-1902. PubMed ID: 32160764 [TBL] [Abstract][Full Text] [Related]